Quarterly ResultAug 5, 2026, 04:19 PM
Vir Biotechnology Q2 Net Income $80.1M; Cash $1.01B; Positive Trial Data
AI Summary
Vir Biotechnology reported a net income of $80.1 million for Q2 2026, a significant improvement from a net loss of $111.0 million in Q2 2025, driven by $238.9 million in revenues from its collaboration with Astellas. The company ended the quarter with over $1.01 billion in cash, cash equivalents, and investments. Positive Phase 2 SOLSTICE data for chronic hepatitis delta was presented, and progress was made in the prostate cancer program with new Phase 1 dose-expansion cohorts initiated for VIR-5500.
Key Highlights
- Q2 2026 net income was $80.1M ($0.47 diluted EPS) vs. $111.0M net loss in Q2 2025.
- Total Q2 2026 revenues were $238.9M, primarily from Astellas collaboration.
- Ended Q2 2026 with $1.01B in cash, cash equivalents, and investments.
- Received $240.0M upfront payment and $75M equity investment from Astellas.
- Phase 2 SOLSTICE data showed 88% of participants achieved undetectable HDV RNA.
- Topline data from Phase 3 ECLIPSE 1 trial expected in Q4 2026.
- Initiated new Phase 1 dose-expansion cohorts for VIR-5500 in prostate cancer.
- Appointed Timothy Coughlin to Board of Directors and as Audit Committee Chair.
Price Impact
More from VIR